Skip to content
Clinical Trials – home
SloveniaBack to Slovenia

Clinical trials in Sempeter Pri Gorici – page 15

392 clinical trials in Sempeter Pri Gorici, Slovenia. Every trial is listed in the EU Clinical Trials Register and updated daily.

SloveniaOur site in SloveniaKlinicnaPreskusanja.si(opens in a new tab)
Sempeter Pri Gorici at a glance
392
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

392 trials in Sempeter Pri Gorici

Open in trial search

Diabetic retinal oedema

Not yet recruiting

Efficacy and safety of intravitreal MK-8748 versus aflibercept in adults with diabetic macular edema

Registered drugNo placebo
Countries:CroatiaCroatia
  • Participants:18–64 years · 65+ years
  • Substances:Aflibercept
  • Sponsor:Merck Sharp & Dohme LLC

Cardiac failure acute+1

Not yet recruiting

Efficacy of istaroxime versus placebo (sodium chloride) infusion in patients with cardiogenic shock due to acute heart failure

Registered drug
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Istaroxime
  • Sponsor:Seismic Pharmaceuticals Operations LLC

Oesophageal adenocarcinoma

Not yet recruiting

Phase II study of tislelizumab plus drug combination as intensified neoadjuvant and adjuvant therapy for resectable esophageal adenocarcinoma patients

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Centro Di Riferimento Oncologico Di Aviano

Abdominal infection+4

Not yet recruiting

Study of Subcutaneous Ceftazidime and Avibactam in Adults with Complicated Intra‑Abdominal, Urinary Tract, or Hospital‑Acquired Pneumonia Infections

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Avibactam
  • Sponsor:Azienda Sanitaria Universitaria Friuli Centrale

Anaemia+1

Not yet recruiting

Study of Elritercept (TAK‑226) with Ruxolitinib vs Placebo in Patients with Myelofibrosis and Anemia on Ruxolitinib Therapy

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Elritercept
  • Sponsor:Takeda Development Center Americas Inc.

Osimertinib and drug combination in metastatic non‑small cell lung cancer with targetable genomic driver alterations

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Adagrasib
  • Sponsor:Universita' Degli Studi Di Torino

Non-small cell lung cancer

Not yet recruiting

Ivonescimab with drug combination in patients with asymptomatic brain metastases from non‑small cell lung cancer – randomized phase II trial

Registered drugNo placebo
Countries:SloveniaSlovenia
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Europese Organisatie Voor Onderzoek En Behandeling Van Kanker Organisation Europeenne Pour La Recherche Et Le Traitement Du Cancer European Organi

Sjogren's syndrome

Not yet recruiting

A Phase 2a/b Study of DDY391 to Evaluate Efficacy, Safety and Tolerability in Adults with Sjögren's Disease

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Sponsor:Novartis Pharma AG

Alcoholic liver disease

Not yet recruiting

Safety and Efficacy of Efimosfermin Alfa vs Placebo in Adults with Alcohol-Related Liver Disease

Investigational
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Efimosfermin alfa
  • Sponsor:Glaxosmithkline Research & Development Limited

Psoriatic arthropathy

Not yet recruiting

Add‑on Unsaturated Fatty Acids with TNF‑Alpha Inhibitor Drug Combination in Patients with Psoriatic Arthritis

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Adalimumab
  • Sponsor:Fondazione Policlinico Universitario Campus Bio-medico In Forma A Bbreviata Fon

Phase II Study of Cemiplimab to Spare Surgery in Patients with Locally Advanced Cutaneous Squamous Cell Carcinoma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Cemiplimab
  • Sponsor:Fondazione GONO Plus

Psoriatic arthropathy

Not yet recruiting

A Study of Guselkumab and Ciclosporin in Patients with Early Psoriatic Arthritis Transitioning from Skin to Joint Disease

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Ciclosporin
  • Sponsor:Azienda Sanitaria Universitaria Friuli Centrale

Other cities in Slovenia

The busiest research cities in the country

All 18 cities in Slovenia

Clinical research in Sempeter Pri Gorici

What the registry says about research in the country

01 Diseases of the Digestive System

Clinical trial research in Sempeter Pri Gorici includes studies focused on digestive system diseases, with attention on improving care for people living with ulcerative colitis. The trials are looking at new treatment options that may help better control inflammation and support symptom management.

  • Key field: gastroenterology
  • Main disease studied: ulcerative colitis
  • Research goal: comparing the effectiveness and safety of newer therapies

These studies are designed to strengthen treatment choices for adults with moderate to severe disease.

02 Nutritional and Metabolic Diseases

Another active area covers nutritional and metabolic diseases, especially type 2 diabetes. Research here is centered on finding better ways to lower blood sugar and improve overall metabolic control in people whose diabetes is not yet adequately managed.

  • Key field: endocrinology
  • Main disease studied: type 2 diabetes
  • Research goal: testing a new therapy against an established treatment
  • Clinical focus: improving glucose control and supporting weight management

The local trial activity reflects a clear interest in refining long-term treatment approaches for diabetes.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.